We assessed regulation of volume-sensitive Cl 2 current (I Cl,swell ) by endothelin-1 (ET-1) and characterized the signalling pathway responsible for its activation in rabbit atrial and ventricular myocytes.
Introduction
Endothelins (ET-1, ET-2, and ET-3) are autocrine/paracrine signalling molecules and growth factors produced and released by vascular endothelium, cardiomyocytes, and other cells. Up-regulation of ET-1, the major cardiac myocyte isoform, is observed in cardiovascular disorders including congestive heart failure, myocardial ischaemia, atrial fibrillation, hypertension, and sepsis-induced dysfunction. 1 This peptide modulates cardiac contractile and electrical activity, and it is a potent mitogenic, fibrotic, and inflammatory factor that contributes to structural remodelling and triggers pro-survival signalling. ET-1 acts primarily via G protein-coupled ET A receptors, which are much more abundant on cardiomyocytes than ET B receptors.
The effects of ET-1 on cardiac electrical activity are complex. In atria, for example, ET-1 abbreviates action potential duration and modulates L-type Ca 2+ , ACh-activated K + , and inwardly rectifying K + currents. 2, 3 Moreover, endothelins regulate the volume-sensitive Cl 2 current, I Cl,swell . After first eliciting I Cl,swell by osmotic swelling or hydrostatic inflation of atrial cells, Du and Sorota 4 reported that ET-1 and ET-2 further augment the current, but the underlying signalling mechanisms are unknown.
Osmotic swelling and stretch of b 1D integrins stimulate I Cl,swell in ventricular myocytes via angiotensin II (AngII) AT 1 receptors, epidermal growth factor receptor (EGFR) kinase, and phosphoinositide-3-kinase (PI-3K) signalling that leads to production of reactive oxygen species (ROS) by NADPH oxidase (NOX). 5 -8 Hydrogen peroxide (H 2 O 2 ) appears to be the active species; I Cl,swell activation is reversed by catalase, and exogenous H 2 O 2 elicits I Cl,swell . ROS generated by NOX and exogenous H 2 O 2 also stimulate I Cl,swell in HeLa and haematoma cells, 9,10 cultured primary astrocytes, 11 and microglia. 12 The signalling that triggers I Cl,swell overlaps pathways implicated in the cardiac response to endothelin. Endothelins are downstream effectors for several actions of AngII, 13 -15 are released by mechanical stretch, 14, 15 and activate EGFR kinase 16 and PI-3K. 17 ROS production is also necessary for at least some of the endothelin-dependent responses in heart. 18, 19 We tested the hypothesis that ET-1 activates I Cl,swell in atrial myocytes 4 by the same pathway triggered by osmotic swelling and AngII in ventricular myocytes. We found that ET-1 elicited I Cl,swell via ET A receptors under isosmotic conditions and that ET A receptors were downstream effectors for osmotic swelling-and AngII-induced I Cl,swell .
In contrast, ET-1 -ET A receptors were upstream to EGFR kinase and PI-3K. Furthermore, ET-1-induced current and ROS production were fully inhibited by blocking either NOX or mitochondrial electron transport, whereas interventions that more directly augmented mitochondrial ROS production were insensitive to NOX inhibitors. Confirming results in atria, ET-1 evoked DCPIB-sensitive I Cl,swell via ET A receptors and both NOX and mitochondrial ROS in ventricular myocytes. These data suggest that ET-1 regulates I Cl,swell as part of a complex signalling cascade that ultimately triggers mitochondrial ROS production.
Methods
This study conforms to Guide for the Care and Use of Laboratory Animals (NIH Publication 85- 23, 1996) and was approved by Virginia Commonwealth University Institutional Animal Care and Use Committee (AM10290). Expanded Methods are available in Supplementary material online.
Atrial and ventricular myocytes were isolated from New Zealand white rabbits (2.8-3.4 kg) using collagenase (Cls 4) and pronase (Type XIV). 5, 6 Recordings were made in the whole-cell patch-clamp mode. Successive 500 ms steps were made from 260 mV to potentials between 2100 and +60 mV in +10 mV increments, and current-voltage (I-V ) relationships were plotted from quasi-steady-state currents.
ROS was detected by flow cytometry (EPICS XL; Beckman Coulter) of mouse atrial HL-1 cells loaded with C-H 2 DCFDA-AM (2.5 or 5 mmol/L), which primarily detects H 2 O 2 . This permitted analysis of cell populations and accurate cell-by-cell quantification of ROS production.
Solutions (C and F ) Currents at +60 mV in Ctrl, after ET-1, and after exposed to DCPIB (n ¼ 5) or 1.5T (n ¼ 4) in the presence of ET-1. **P , 0.01.
Results
3.1 ET-1 activates I Cl,swell via ET A receptors Figure 1A -C shows that ET-1 rapidly elicited an outwardly rectifying Cl 2 current in atrial myocytes in isosmotic solutions that reversed near the Cl 2 equilibrium potential, -43 mV. The ET-1-induced current was abolished by adding DCPIB, a highly selective I Cl,swell inhibitor. Overall, ET-1 increased Cl 2 current at +60 mV from 0.54 + 0.04 to 1.80 + 0.10 pA/pF (n ¼ 61, P , 0.01), and DCPIB blocked 99 + 4% (n ¼ 5, P , 0.01) of the increase. The half-time for activation was 5.1 + 0.5 min (n ¼ 9), and current was maintained for at least 45 min (n ¼ 3). Furthermore, 95 + 6% (n ¼ 4, P , 0.01) of ET-1-induced current was inhibited by osmotic shrinkage in 1.5T bath solution containing ET-1 ( Figure 1D-F Figure S1 ). Exposure to BQ123 (10 mmol/L, 5-10 min), a selective ET A inhibitor, suppressed ET-1-induced currents by 90 + 3% (n ¼ 4, P , 0.01), whereas the selective ET B blocker BQ788 (100 nmol/L, 15-20 min) was ineffective (n ¼ 4, NS).
Supplementary material online, Figure S2 , shows that ET-1 also regulated I Cl,swell in ventricular myocytes. The ET-1-induced current was 3.3 + 0.4 pA/pF at +60 mV (n ¼ 16, P , 0.01) and was fully suppressed by DCPIB (93 + 6%; n ¼ 4, P , 0.01). Moreover, the response to ET-1 was fully blocked by adding BQ123 (97 + 2%; n ¼ 4 P , 0.01), implicating ET A receptors in ventricular as well as atrial myocytes.
Role of ET-1 and ET A receptors in signalling
Stimulation of I Cl,swell by b 1D integrin stretch, osmotic swelling, or exogenous AngII in ventricular myocytes requires the sequential activation of AngII AT 1 receptors, EGFR kinase, and PI-3K. 5, 7, 8 Because
AngII can act via ET-1 and ET A receptors 13, 19 and ET-1 activates EGFR kinase in cardiac myocytes, 16 we tested the hypothesis that ET A receptors are upstream from EGFR kinase and PI-3K and downstream from AT 1 receptors and osmotic swelling in the signalling pathway for I Cl,swell . Figure 2A illustrates the effect of blocking downstream signalling in atrial myocytes. As predicted, selective inhibition of EGFR kinase with AG1478 suppressed ET-1-induced I Cl,swell by 88 + 3% (n ¼ 5, P , 0.01), and exogenous EGF (10 nmol/L, 10 min) activated I Cl,swell (n ¼ 9, P , 0.01). Moreover, inhibiting PI-3K with LY294002 or wortmannin abrogated ET-1-induced current, blocking 102 + 7% (n ¼ 4, P , 0.02) and 92 + 3% (n ¼ 4, P , 0.01), respectively ( Figure 2B ). The role of ET A receptors in responding to upstream signalling is depicted in Figure 2C -E. If ET A receptors are downstream from AT 1 receptors, BQ123 should block AngII-induced I Cl,swell , whereas the AT 1 receptor blocker losartan should be ineffective in suppressing ET-1-induced I Cl,swell . Consistent with this idea, AngII increased current at +60 mV from 0.40 + 0.02 to 1.38 + 0.24 pA/pF, and BQ123 blocked 92 + 2% (n ¼ 5, P , 0.01) of AngII-induced current in the presence of AngII. In contrast, the AT 1 receptor blocker losartan did not alter ET-1-induced I Cl,swell (n ¼ 4, NS).
The proposed scheme also predicts that blockade of ET A receptors should suppress the activation of I Cl,swell by osmotic swelling ( Figure 2E) . Osmotic swelling increased current at +60 mV from 0.67 + 0.16 to 1.80 + 0.42 pA/pF, and adding BQ123 to 0.7T solution blocked 91 + 4% of swelling-induced current (n ¼ 4, P , 0.01). In the presence of BQ123, both the swelling-induced current in 0.7T and AngII-induced current in 1T were indistinguishable from 1T control currents.
Reactive oxygen species
I Cl,swell activation by stretch, osmotic swelling, AngII, and EGF requires ROS, and exogenous H 2 O 2 elicits I Cl,swell at a downstream site. 5, 7, 8 To test whether ET-1 also utilizes ROS as a downstream effector in atrial myocytes, we used ebselen, a membrane-permeant glutathione peroxidase mimetic that scavenges H 2 O 2 . Figure 3 shows that the stimulation of I Cl,swell by ET-1 was fully reversed by adding ebselen. Ebselen blocked 113 + 10% (n ¼ 4, P , 0.01) of ET-1-induced current. As expected if ebselen scavenges H 2 O 2 , exogenous H 2 O 2 rapidly activated I Cl,swell (n ¼ 4, P , 0.01), as previous shown in the ventricle. 5, 7, 8 What is the source of ROS? One possibility is NOX. NOX subunit assembly and ROS production are stimulated by AngII, PI-3K, and ET-1, 21, 22 and block of NOX suppresses swelling-and stretch-induced I Cl,swell in ventricular myocytes 5, 7, 8 and other cells. 9 -12 To assess whether ET-1 depends on NOX to evoke I Cl,swell , we used apocynin and the fusion peptide gp91ds-tat, two chemically distinct inhibitors of NOX assembly. Figure 4A -C demonstrates that adding apocynin suppressed 86 + 6% (n ¼ 5, P , 0.01) of ET-1-induced current in atrial myocytes, and current after block was not significantly different than control. Similarly, adding gp91ds-tat suppressed 101 + 5% (n ¼ 4, P , 0.01) of ET-1-induced I Cl,swell ( Figure 4C ). Although these data implicate NOX as a required source of ROS in ET-1 signalling, NOX may not be a sufficient source. An important alternative is mitochondria, and the complex III Q cycle is a major site for extra-mitochondrial ROS release. Rotenone, a selective complex I inhibitor, suppresses electron flow to complex III and inhibits ROS generation by intact cardiac mitochondria. As shown in Figure 4D -F, adding rotenone to ET-1 blocked 85 + 4% (n ¼ 4, P , 0.01) of ET-1-induced current in atrial myocytes and restored current to its control value. I Cl,swell evoked by ET-1 in ventricular myocytes also was fully abrogated by both gp91ds-tat (102 + 0.8%, n ¼ 4, P , 0.01) and rotenone (105 + 0.8%, n ¼ 4, P , 0.01), as shown in Supplementary material online, Figure S3 . Finding inhibitors of NOX and mitochondrial ROS production both completely blocked I Cl,swell suggests that these ROS sources are likely to act in series rather than by independent pathways.
To verify that mitochondrial ROS can activate I Cl,swell , we used electron transport chain inhibitor antimycin A and the mitochondrial ATP-sensitive K + channel (mitoK ATP ) agonist diazoxide; both stimulate mitochondrial ROS production at complex III. As expected, if mitochondrial ROS participate, both antimycin A and diazoxide elicited atrial I Cl,swell ( Figure 5A and B) . Antimycin A increased Cl 2 current at +60 mV from 0.54 + 0.11 to 1.40 + 0.14 pA/pF (n ¼ 11, P , 0.01) and diazoxide from 0.60 + 0.13 to 1.78 + 0.47 pA/pF (n ¼ 5, P , 0.02). Next, we tested whether production of ROS by NOX was downstream from mitochondrial ROS in the pathway regulating I Cl,swell . Contrary to this idea, I Cl,swell evoked by antimycin A and diazoxide was insensitive to two NOX blockers, apocynin (n ¼ 5, NS) and the membrane-permeant fusion peptide gp91ds-tat ( Figure 5A : n ¼ 6, NS;
Figure 5B: n ¼ 5, NS). Taken together, Figures 4 and 5 suggest that mitochondria must be downstream from NOX in the I Cl,swell signalling cascade. Osmotic shrinkage fully blocks I Cl,swell elicited by exogenous ET-1 (Figure 1) , EGF, and upstream signalling effectors, but shrinkage fails to reverse I Cl,swell activation by exogenous H 2 O 2 , which is the furthest downstream regulator identified to date.
8 Figure 5C -E demonstrates that mitochondrial ROS production elicited by antimycin A also was insensitive to osmotic shrinkage in 1.5T bath solution (n ¼ 4, NS). These data imply that mitochondrial ROS production is a distal step in the cascade and is downstream to the site of action of osmotic shrinkage.
Measurement of ROS production
ET-1-induced ROS production was directly assessed in atrial HL-1 myocytes by flow cytometry after loading cells with C-H 2 DCFDA-AM, a fluorophore that senses H 2 O 2 . ET-1 itself was not fluorescent in the absence of the probe ( Figure 6A and D) . Basal ROS production (Ctrl) was detected in C-H 2 DCFDA-AM-loaded cells, and exposure to ET-1 significantly augmented fluorescence; exogenous H 2 O 2 served as a positive control ( Figure 6B and D) . Importantly, pre-treatment with either rotenone or gp91ds-tat fully prevented ET-1-induced ROS production Figure 6C and D) , consistent with the idea that NOX and mitochondria must act in series. Flow cytometry also confirmed that antimycin A-induced mitochondrial ROS production was independent of NOX. Antimycin A increased ROS production 3.6-fold (n ¼ 3, P , 0.05).
After pre-treatment with gp91ds-tat, antimycin A still elevated ROS production 3.5-fold (n ¼ 3, P , 0.05), whereas pre-treatment with rotenone decreased antimycin-induced ROS production to 1.2-times background (n ¼ 3, NS). Thus, mitochondrial ROS production must be downstream from NOX, as also suggested by the electrophysiological data.
Discussion
Endothelins were initially reported to modulate I Cl,swell after the current was first activated by osmotic swelling or hydrostatic inflation of atrial myocytes. 4 We found that I Cl,swell was also elicited by ET-1 via ET A receptors under isosmotic conditions in both atrial and ventricular myocytes, identified its position the signalling cascade, and demonstrated the involvement of ROS production by NOX and mitochondria. A diagram summarizing the I Cl,swell cascade is presented in Figure 7 . Although components of this pathway were known to regulate I Cl,swell in cardiomyocytes, the role of ET-1 and obligatory mitochondrial ROS production was not previously recognized. 10 and blocking PI-3K inhibits I Cl,swell in pulmonary artery smooth muscle. 23 Nevertheless, the proposed scheme may be an over simplification. We did not establish whether the response to swelling is due to an autocrine/paracrine release of endothelin and/ or AngII or another mechanism. AT 1 receptors appear to be activated by stretch in the absence of AngII binding, 24 but an analogous mechanism has not been explored for ET A receptors. Alternatively, formation of AT 1 -ET A heterodimers might modulate crosstalk, as found for heterodimers between several G protein-coupled receptors. 25 Src-dependent transactivation of ET A by AT 1 reported in mesenteric arteries 26 seems unlikely because blocking Src stimulates rather than inhibits osmotic swelling-induced I Cl,swell in cardiac myocytes. 5, 27 Owing to the rapidity of the response, it also seems unlikely that osmotic swelling and AngII act by altering ET-1 synthesis. Finally, contributions from other branches of the signalling cascade triggered by ET A receptors and from feedback by ROS that modulates signalling cannot be excluded.
Reactive oxygen species
Activation of I Cl,swell by swelling, stretch, AngII, and EGF has been attributed to ROS production by NOX in cardiac myocytes 5, 7, 8 and other cells. 9 -12 H 2 O 2 is thought to be the active ROS because I Cl,swell activation is reversed by catalase and exogenous H 2 O 2 elicits the current. ET-1-induced I Cl,swell studied here must also depend on ROS production because it was suppressed by ebselen, a glutathione peroxidase mimetic that scavenges H 2 O 2 . Although NOX activity was required for ET-1 to elicit both I Cl,swell and ROS production, we found that it was not a sufficient stimulus. Blocking either NOX with apocynin or gp91ds-tat or mitochondrial ROS production with rotenone fully suppressed both ET-1-induced I Cl,swell and ROS production. This suggests that the NOX and mitochondria must have acted in series. If instead these ROS generators lead to independent paths, blocking only one would be expected to give partial inhibition. It seems likely that NOX was an upstream trigger for mitochondrial ROS production by complex III. Activation of I Cl,swell was mimicked by augmenting mitochondrial complex III ROS production with antimycin A, an inhibitor of mitochondrial electron transport distal to the Q o site in complex III, or diazoxide, a mitoK ATP channel opener. Furthermore, both the resulting current and ROS-induced fluorescence were insensitive apocynin and gp91ds-tat. Therefore, mitochondria must be downstream from NOX in the cascade activating I Cl,swell . Superoxide (O 2 2 † ) produced by NOX rapidly undergoes dismutation to H 2 O 2 , a longer-lived, membrane-permeant species. ROS may stimulate mitochondrial ROS production by several mechanisms. First, mitochondria can undergo ROS-induced ROS release, a process by which an initial release of ROS triggers oscillations of mitochondrial potential and ROS release that propagates from mitochondrion to mitochondrion. 28 21, 33 Moreover, both apocynin and gp91ds-tat act by preventing subunit assembly that is required for ROS production by NOX2. In contrast, NOX4 is generally considered constitutively active and is insensitive to subunit assembly blockers. 33 Apocynin does not alter O 2 2 † production by cardiac mitochondria 34 but appears to inhibit P450 monooxygenase in endothelial cells. 35 The fusion peptide gp91ds-tat 36 is thought to be highly selective because it contains the 9-mer-binding site from gp91 phox (NOX2) that associates with p47 phox or its homologues (e.g. NOXO1, assembles with NOX1).
Rapid induction of cardiac NOX-dependent ROS production by ET A receptor activation initial was reported in cultured neonatal rat myocytes. 37 Recently, mechanical stretch, AngII/AT 1 receptors, 38 and ET-1/ET A receptors 39 also were shown to rapidly augment ROS production in cat ventricular myocytes by NOX-and mitochondria-dependent processes. These authors did not identify the interaction between the sources of ROS or the signalling cascade. Signalling regulating ROS production is highly tissue-and species-dependent, however. Whereas AngII-induced ROS produced in rat vascular smooth muscle peaks in 10 min, it takes 6 h when ET A receptors are stimulated with ET-1. 40 In human vascular smooth muscle, AngII-induced activation of NOX is suppressed by apocynin, but blocking NOX has no effect on ET-1-induced ROS. 41 Rather,
ET-1-triggered ROS production was suppressed by inhibiting mitochondrial complex II with TIFT, complex IV with CCCP, but not blocking complex I with rotenone.
Implications
Thinking of I Cl,swell as a current regulated by NOX and mitochondrial ROS rather than a current regulated by cell volume or stretch may help clarify its role. ROS production is augmented in a variety of ET-1/ET A signalling regulates I Cl,swell via ROS physiological and pathophysiological settings, and up-regulation of ET-1 occurs in congestive heart failure, myocardial ischaemia, atrial fibrillation, hypertension, and sepsis-induced dysfunction. 1 We suspect that the same signalling cascade described here is likely to regulate I Cl,swell in human cardiac disease, but to date only the involvement of EGFR kinase has been studied in atrial myocytes from patients. 6 If I Cl,swell is activated in human disease, it may influence outcomes by modulating action potential duration, cardiac cell volume, cell growth, and apoptosis. Moreover, in addition to I Cl,swell , NOX and mitochondrial ROS production triggered by this signalling cascade are very likely to influence other ion channels and transporters in the heart.
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